Colon Cancer: Symptoms, Causes, Treatment & Nursing Care

Early cancers may be asymptomatic and picked up only via screening colonoscopy. Symptomatic disease often reflects luminal narrowing, occult blood loss, or transmural inflammation.

Common features

• Altered stool caliber or constipation/diarrhoea patterns
• Fatigue from chronic anemia or advanced disease
• Visible blood or melena-type stool (right-sided lesions may bleed slowly)
• Left-sided lesions: obstructive cramps, tenesmus (if low rectal overlap)

Features that should increase urgency

• Unintentional weight loss, anorexia, or performance decline
• Iron deficiency pattern on CBC without obvious benign cause
• New ascites, palpable mass, or jaundice suggesting advanced spread

Most cases are sporadic, arising from interaction between inherited susceptibility, somatic mutations, and modifiable exposures. Chronic intestinal inflammation and inherited polyposis syndromes accelerate neoplastic change.

Non-modifiable

• Increasing age
• Family history of colorectal cancer or advanced polyps
• Lynch syndrome (MMR mutation carriers) and familial adenomatous polyposis pathways
• Long-standing ulcerative colitis or Crohn disease involving the colon

Modifiable / lifestyle (clinician-facing)

• Processed and red meat–heavy diets, low fibre, cigarette smoking, excess alcohol, obesity, and sedentary physiology
• Type 2 diabetes and insulin resistance clusters (risk marker, not sole cause)

Diagnostic workup confirms histology, defines local extent, and screens for metastases so the MDT can assign stage and recommend treatment sequencing.

Clinical assessment

• Digital rectal examination when indicated; assess for masses, nodal regions, and peritoneal signs
• Pain assessment and baseline functional status for fitness scoring

Laboratory investigations

• CBC (anemia, thrombocytosis), renal and liver chemistries, coagulation if bleeding
• Inflammatory markers such as CRP when infection or flare mimics malignancy
• Tumour marker CEA may support follow-up trends but is not a screening test

Endoscopy & imaging

• Colonoscopy with biopsy or tattooing of lesions for surgical orientation
• CT chest/abdomen/pelvis for metastatic survey; MRI pelvis when rectal involvement suspected
• When colitis overlap is unclear, fecal calprotectin can help triage IBD flare vs infection—but does not replace cancer pathway if red flags persist

Diagnostic criteria / scoring in practice

Formal “scores” matter less than explicit pathway criteria: age bands for screening, threshold symptoms prompting two-week-wait or equivalent referrals, and histologic confirmation before systemic therapy except rare emergencies.

1. Screen-detected lesion: endoscopic resection if suitable; histology determines surveillance interval.
2. Symptomatic patient: labs + dedicated GI investigation; avoid reassuring solely on IBS label without appropriate exclusion.
3. Confirmed cancer: staging imaging, MDT consensus, fitness assessment.
4. Localized surgical candidate: resection ± port placement; pathology drives adjuvant discussion.
5. Metastatic disease: systemic regimen per biomarkers; early palliative care integration for symptom control.
6. Treatment failure: objective progression on imaging or rising symptoms triggers regimen switch—managed only by oncology.

↔On a small screen, swipe or scroll sideways to see the full table.

Treatment selection requires MDT input; nursing responsibilities focus on preparation, administration safety, toxicity surveillance, and coordinated education.

Surgery-first for localized colon cancer

Hemicolectomy or extended resection with lymphadenectomy remains curative intent for operable colon primaries. Enhanced recovery pathways emphasise early mobilisation, optimised analgesia, and VTE prophylaxis.

Adjuvant & neoadjuvant systemic therapy (themes)

• Stage III colon cancer commonly receives adjuvant fluoropyrimidine ± oxaliplatin for up to ~6 months per tolerability—exact regimen from protocol.
• Rectal cancers may require long-course chemoradiotherapy before surgery; colon primaries rarely need routine radiotherapy except selective oligometastatic or palliative plans.
• Metastatic first-line often combines fluorouracil backbone with platinum or other agents plus biologics when biomarkers fit.
• MSI-H/dMMR metastatic disease may qualify for immune checkpoint inhibitors—document immune-related adverse events vigilantly.

Supportive medication partners

• Antiemetics (ondansetron, metoclopramide) and bowel regimens including lactulose when opioids slow transit—only after obstruction excluded
• Analgesia layered per WHO-style ladders; acetaminophen for mild pain if hepatology permits

Stoma pathways

Some resections require temporary or permanent stomas; preoperative marking and postoperative ostomy care teaching reduce complications and readmissions.

• Pre-treatment: Verify histology, staging studies, cardiac risk, dental review when bisphosphonates or certain supportive meds planned, nutrition baseline.
• Chemotherapy cycles: Pre-chemo labs, allergy verification, infusion line patency, hydration orders, home medication reconciliation.
• Monitoring intervals: Surveillance colonoscopy and imaging timelines post curative therapy follow hospital guidelines—often intensified in year 1–2 then spaced if clear.
• Drug–drug checks: Warfarin/DOAC interactions, QT-prolonging antiemetics with additional risk factors, DPD testing when locally mandated for fluoropyrimidines.
• Treatment failure criteria: Radiologic progression, performance decline, or intolerable toxicity prompting MDT reconsideration—nursing documentation of trends accelerates decisions.
• Referral thresholds: Suspected obstruction, uncontrolled pain, unmanageable dehydration, or first-cycle severe reaction triggers acute oncology or ED pathways.

Local / surgical: anastomotic leak, ileus, wound infection, venous thromboembolism. Oncologic emergencies: bowel obstruction, perforation, hemorrhage. Systemic therapy: neutropenia with infection, severe diarrhea (Clostridioides difficile vs secretory), mucositis, palmar-plantar erythrodysesthesia, acute neuropathy, cardiotoxicity with selected agents. Immune therapy adds endocrinopathy, colitis, hepatitis, pneumonitis spectrum—report new cough, bilirubin rise, or watery stool promptly.

Organised screening (FIT, colonoscopy, or recommended alternatives by age and risk) removes precancerous polyps and detects early cancers. USPSTF, NICE, ACS, and national programmes differ on start/stop ages—apply the jurisdiction’s schedule. High-risk cohorts (Lynch carriers, IBD) require intensified colonoscopic surveillance. Address smoking cessation, weight management, and alcohol moderation as part of holistic risk reduction.

Outcomes correlate with stage at detection, completeness of resection, nodal burden, circulating tumor dynamics, and treatment responsiveness. Localised disease carries favourable population survival; metastatic disease is often controllable for extended intervals but remains incurable for many, underscoring honest goal-of-care conversations led by senior clinicians.

Translate subtle changes into objective data: orthostatic vitals with blood loss, stool frequency charts during chemotherapy, accurate Emesis grading, and pain scores that rise despite baseline analgesia. Language barriers or health literacy gaps may hide bowel symptoms—use teach-back for ostomy and neutropenic precautions. Document notifications to surgical teams when flatus stops, drains darken, or lactate drifts upward postoperatively.

• Vital signs including temperature and pain score each round during acute admissions.
• Drain outputs, NG losses, and stool frequency consistency recorded on flow sheets.
• Strict I&O during diuretic phases or sepsis resuscitation.
• Daily skin checks for device sites and hand-foot skin changes on chemotherapy.
• Mental status screening if infection, opioid load, or metabolic derangement suspected.

• Hemodynamic shock with suspected GI bleed or perforation
• Feculent vomiting, rising lactate, or overt peritonism
• Febrile neutropenia (temperature ≥38.3°C once or ≥38.0°C sustained) during or shortly after chemotherapy
• Stridor, laryngeal spasm sensation after oxaliplatin with airway compromise

Objective triggers: NEWS/MEWS rise, new oxygen requirement, oliguria despite fluids, bilirubin or creatinine jump, platelets falling below protocol thresholds, inability to tolerate PO fluids. Ward actions: repeat obs, escalate to senior nurse and on-call registrar, activate sepsis or major hemorrhage pathway, recheck electrolytes and lactate. Senior review targets: rapid CT if abdomen unsafe, surgical re-look vs interventional radiology for bleed, critical care if multi-organ support needed.

Pre-treatment education

• Teach cold sensitivity strategies for oxaliplatin schedules and differentiate expected tingling from progressive neuropathy.
• Explain expected diarrhea grading and when to call—the threshold differs for immunotherapy colitis vs chemotherapy enteropathy.

Postoperative recovery

• Incentive spirometry, early mobilisation, and balanced multimodal analgesia while monitoring ileus cues.
• Coach stoma patients in appliance changes; involve stoma nurses early.

Evaluation

• Compare daily weights, oral intake, and functional scores; flag unplanned losses >5% body weight weekly.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of colorectal cancer screening (FIT / colonoscopy), MDT-led TNM staging, structured surgery + adjuvant chemotherapy and the bowel-obstruction / perforation / febrile-neutropenia red flags.